{"id":"W2989894179","doi":"10.1016/s1470-2045(19)30684-9","title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":644,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research","funders":"Prostate Cancer UK; Public Health Agency; Division of Research, Evaluation, and Communication; Prostate Cancer Foundation; Movember Foundation; AstraZeneca; Medical Research Council; Institute of Cancer Research; Cancer Research UK; Royal Marsden NHS Foundation Trust; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; U.S. Department of Veterans Affairs","keywords":"Olaparib; Medicine; Prostate cancer; Open label; Oncology; Internal medicine; Urology; Cancer; Randomized controlled trial; Gene; Biology; Poly ADP ribose polymerase; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002433076,0.001935737,0.002330651,0.000448206,0.000393821,0.001336524,0.0009130043,0.001851695,0.005822424],"category_scores_gemma":[0.001858405,0.0006424907,0.001382755,0.0005374866,0.0008918139,0.001148846,0.0005436469,0.002512766,0.0008092495],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006454837,"about_ca_system_score_gemma":0.001269834,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005856806,"about_ca_topic_score_gemma":0.001195686,"domain_scores_codex":[0.9992126,0.000487193,0.00003331491,0.0001059837,0.00005477144,0.0001059721],"domain_scores_gemma":[0.999079,0.0002170127,0.0002193713,0.0000679002,0.00005409833,0.0003626388],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9717975,0.005055234,0.0007192008,0.0007902778,0.000506382,0.000101158,0.00006477086,0.000422539,0.003494458,0.0001072731,0.001020008,0.01592123],"study_design_scores_gemma":[0.9483895,0.04944321,0.0009809063,0.00002190211,0.0001292761,0.00006934965,0.00001137895,0.0002093377,0.0001720227,0.00009408886,0.0004681488,0.00001092915],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9832085,0.005605121,0.0006719131,0.0009921258,0.0005001617,0.005734533,0.001514823,0.0001394279,0.001633398],"genre_scores_gemma":[0.9812966,0.003407742,0.002006032,0.001504394,0.0006339751,0.00696894,0.001551245,0.00002953757,0.002601483],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005822424,"threshold_uncertainty_score":0.01947796,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06985848620486315,"score_gpt":0.3983035503391584,"score_spread":0.3284450641342952,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}